ODI PHARMA AB (6OD) — Working Capital to Net Assets Ratio
ODI PHARMA AB (6OD) has a Working Capital to Net Assets ratio of 99.5% as of June 2026. Working capital of €2.36 Million (current assets of €5.29 Million minus current liabilities of €2.93 Million) is measured against net assets of €2.38 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See ODI PHARMA AB (6OD) defensive interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ODI PHARMA AB Working Capital to Net Assets (2022–2026)
This chart shows how ODI PHARMA AB's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2022 to 2026. As of June 2026, the ratio stands at 99.5%, reflecting working capital of €2.36 Million against net assets of €2.38 Million EUR. For the complete balance sheet picture, see balance sheet size of ODI PHARMA AB.
Annual Working Capital to Net Assets for ODI PHARMA AB (2022–2026)
The table below presents the year-by-year Working Capital to Net Assets ratio for ODI PHARMA AB from 2022 to 2026, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read ODI PHARMA AB (6OD) financial obligations for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2026 | 99.5% | €2.36 Million | €2.38 Million | €5.29 Million | €2.93 Million | ▲ +236.1 pp |
| 2025 | -136.5% | €-579.84K | €424.64K | €3.61 Million | €4.19 Million | ▼ -236.2 pp |
| 2024 | 99.7% | €1.99 Million | €2.00 Million | €12.22 Million | €10.23 Million | ▲ +0.0 pp |
| 2023 | 99.6% | €2.56 Million | €2.57 Million | €8.18 Million | €5.61 Million | ▼ -0.2 pp |
| 2022 | 99.9% | €9.25 Million | €9.26 Million | €10.48 Million | €1.24 Million | — |